高危前列腺癌立体定向消融放疗联合区域淋巴结照射的1-2期研究(SATURN):早期毒性与生活质量
这项1/2期前瞻性研究纳入30例高危前列腺癌患者,给予盆腔及精囊25 Gy、前列腺同步整合推量至40 Gy,共5次每周照射,联合雄激素剥夺治疗12至18个月。中位随访25.7个月,未观察到3级及以上毒性,2级泌尿毒性急性和晚期分别为46.7%和52%,2级胃肠毒性分别为3.3%和32%,生活质量评分保持稳定。作者认为该方案可行且耐受良好。
要点
- 5次盆腔放疗联合前列腺推量至40 Gy,同时照射盆腔和精囊,联合雄激素剥夺治疗12至18个月。
- 未观察到3级及以上毒性,2级泌尿毒性急性46.7%、晚期52%,2级胃肠毒性急性3.3%、晚期32%。
- EPIC泌尿和肠道生活质量评分从基线至24个月保持稳定。
核心结论
- 作者认为,这种基于机架的新型分割方案联合盆腔照射和雄激素剥夺治疗高危前列腺癌是可行且耐受良好的。
研究设计与样本
- 1/2期前瞻性研究,纳入30例高危前列腺癌患者,完成计划治疗。
- 放疗方案为盆腔和精囊25 Gy,前列腺同步整合推量至40 Gy,共5次,每周照射,总疗程29天。
- 雄激素剥夺治疗持续12至18个月。
- 采用不良事件通用术语标准3.0版评估急性和晚期毒性,采用扩展前列腺癌综合指数问卷评估生活质量。
主要发现
- 中位随访25.7个月(范围18.5-30.7个月)。
- 2级泌尿毒性:急性46.7%,晚期52%。
- 2级胃肠毒性:急性3.3%,晚期32%。
- 未观察到3级及以上毒性。
- EPIC泌尿生活质量评分均值(95%CI):基线86.6(81.9-91.3),3个月87.1(81.4-92.6),24个月87.9(80.1-95.7)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Five-fraction stereotactic ablative radiation therapy appears to be gaining popularity in treatment of prostate cancer, but it has not been extensively tested in the context of pelvic radiation. The objective of this prospective prostate and pelvic SABR study is to report the acute toxicity, late toxicity, and quality of life (QoL) after study completion. METHODS AND MATERIALS: A phase 1/2 study was conducted for patients with high-risk prostate cancer. Radiation therapy was planned to deliver 25 Gy to pelvis and seminal vesicles (SV) and a simultaneous integrated boost (SIB) of up to 40 Gy to the prostate in 5 fractions, weekly, over 29 days. Androgen deprivation therapy was used for 12 to 18 months. Common Terminology Criteria for Adverse Events version 3.0 was used to assess worst acute and late toxicities. QoL data was captured using the Expanded Prostate Cancer Index Composite questionnaire (EPIC). RESULTS: Thirty patients completed the planned treatment with a median follow-up of 25.7 months (range, 18.5-30.7 months). The following "worst" acute and late toxicities were observed: grade 2 genitourinary toxicity, 46.7% and 52%, respectively; grade 2 gastrointestinal toxicity, 3.3% and 32%, respectively. No grade 3 or higher toxicities were noted. Mean (95% confidence interval) EPIC urinary QoL scores were 86.6 (81.9-91.3), 87.1 (81.4-92.6), and 87.9 (80.1-95.7) at baseline, 3 months and 24 months; bowel scores were 94.1 (91.3-97.0), 93.2 (89.1-97.2), and 92.4 (87.7- 97.1), respectively. CONCLUSIONS: This gantry-based novel fractionation schedule incorporating pelvic radiation for high-risk prostate cancer in combination with androgen deprivation therapy is feasible and well tolerated.
引用
- Musunuru HB, D'Alimonte L, Davidson M, et al. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. Int J Radiat Oncol Biol Phys. 2018. PMID: 30071295. doi:10.1016/j.ijrobp.2018.07.2005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。